A. N. Kazakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. N. Kazakova has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Elena Zerkalenkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117198 Moscow, Russia
13 shared publications - Yulia Olshanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
13 shared publications - Aleksandr Mikhailovich Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
12 shared publications - Alexey Aleksandrovich Maschan
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
10 shared publications - Galina. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
9 shared publications - Irina I. Kalinina
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
7 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 289-302
Prognostic factors and long-term treatment outcomes in children with standard-risk acute lymphoblastic leukemia enrolled in the ALL-MB 2008 protocol: a retrospective analysis of 1,702 patients
Introduction . Within the ALL-MB 2008 protocol, the standard-risk group (SRG) was signifi cantly modifi ed, necessitating a detailed study of long-term treatment outcomes. Data analysis of 1,702 newly diagnosed patients allows for evaluating the reproducibility of high survival rates and identifying factors that infl uence the risk of relapse in this cohort. Aim: to evaluate long-term treatment outcomes and identify independent prognostic factors in children with acute lymphoblastic leukemia (ALL) stratified into the SRG of the ALL-MB 2008 protocol. Materials and Methods. A retrospective analysis of data from 1,702 patients (93.5 % of SRG; aged 1–18 years) included in the multicenter ALL-MB 2008 study (2008–2014, 46 participating clinics) was conducted. Survival rates were calculated using the Kaplan–Meier method, the cumulative incidence of relapse (CIR) was estimated using the competing risks method, and multivariate analysis was performed using Cox regression. Database closing date: 01.06.2021, with a median follow-up of 8.7 years. Results . Complete remission (CR) was achieved in 98.5 % of patients. The 12-year event-free survival (EFS) was 86.8 ± 0.8 %, overall survival (OS) was 91.0 ± 0.7 %, the cumulative incidence of relapse (CIR) was 9.0 ± 0.7 %, and treatment-related mortality (TRM) was 4.1 ± 0.5 %. A slow response on day 15 of induction (≥10 % blast cells in the bone marrow [BM]) was associated with a decrease in EFS (78.1 % vs. 89.2 %; p < 0.0001) and an increase in CIR (17.0 % vs. 7.5 %; p < 0.0001). Patients aged ≥10 years had significantly worse EFS (77.5 % vs. 88.3 %; p < 0.0001) and a higher CIR level (18.3 % vs. 7.4 %; p < 0.0001). The presence of the t(12;21)/ETV6::RUNX1 was associated with the most favorable prognosis (EFS 91.7 %). According to the Cox multivariate analysis, independent predictors of unfavorable outcomes were age ≥ 10 years (HR 2.15; 95 % CI 1.49–3.10; p < 0.001) and a slow morphological response on day 15 of induction (HR 1.85; 95 % CI 1.25–2.70; p = 0.002). Conclusion . The outcomes of the ALL-MB 2008 protocol for the standard-risk group are comparable to data from leading international cooperative groups, despite a signifi cant reduction in the intensive chemotherapy phase: omission of high-dose methotrexate and cyclophosphamide, a substantial reduction in the cumulative dose of anthracyclines, and their complete elimination in one-third of patients. Age and early response rate justify further differentiation of therapeutic approaches within the standard-risk group.
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 289-302
Open AccessPrognostic factors and long-term treatment outcomes in children with standard-risk acute lymphoblastic leukemia enrolled in the ALL-MB 2008 protocol: a retrospective analysis of 1,702 patients
Introduction . Within the ALL-MB 2008 protocol, the standard-risk group (SRG) was signifi cantly modifi ed, necessitating a detailed study of long-term treatment outcomes. Data analysis of 1,702 newly diagnosed patients allows for evaluating the reproducibility of high survival rates and identifying factors that infl uence the risk of relapse in this cohort. Aim: to evaluate long-term treatment outcomes and identify independent prognostic factors in children with acute lymphoblastic leukemia (ALL) stratified into the SRG of the ALL-MB 2008 protocol. Materials and Methods. A retrospective analysis of data from 1,702 patients (93.5 % of SRG; aged 1–18 years) included in the multicenter ALL-MB 2008 study (2008–2014, 46 participating clinics) was conducted. Survival rates were calculated using the Kaplan–Meier method, the cumulative incidence of relapse (CIR) was estimated using the competing risks method, and multivariate analysis was performed using Cox regression. Database closing date: 01.06.2021, with a median follow-up of 8.7 years. Results . Complete remission (CR) was achieved in 98.5 % of patients. The 12-year event-free survival (EFS) was 86.8 ± 0.8 %, overall survival (OS) was 91.0 ± 0.7 %, the cumulative incidence of relapse (CIR) was 9.0 ± 0.7 %, and treatment-related mortality (TRM) was 4.1 ± 0.5 %. A slow response on day 15 of induction (≥10 % blast cells in the bone marrow [BM]) was associated with a decrease in EFS (78.1 % vs. 89.2 %; p < 0.0001) and an increase in CIR (17.0 % vs. 7.5 %; p < 0.0001). Patients aged ≥10 years had significantly worse EFS (77.5 % vs. 88.3 %; p < 0.0001) and a higher CIR level (18.3 % vs. 7.4 %; p < 0.0001). The presence of the t(12;21)/ETV6::RUNX1 was associated with the most favorable prognosis (EFS 91.7 %). According to the Cox multivariate analysis, independent predictors of unfavorable outcomes were age ≥ 10 years (HR 2.15; 95 % CI 1.49–3.10; p < 0.001) and a slow morphological response on day 15 of induction (HR 1.85; 95 % CI 1.25–2.70; p = 0.002). Conclusion . The outcomes of the ALL-MB 2008 protocol for the standard-risk group are comparable to data from leading international cooperative groups, despite a signifi cant reduction in the intensive chemotherapy phase: omission of high-dose methotrexate and cyclophosphamide, a substantial reduction in the cumulative dose of anthracyclines, and their complete elimination in one-third of patients. Age and early response rate justify further differentiation of therapeutic approaches within the standard-risk group.
- Open Access
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 107-113
Compensatory clonal hematopoiesis in patients with Shwachman–Diamond syndrome
Introduction. Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome characterized by a high risk of developing myeloid malignancies. Aim: to determine the spectrum of compensatory genetic events in SDS as well as to analyze their potential role in the clinical course of the disease. Materials and methods. The study included 41 patients with confirmed SDS. For the analysis of somatic alterations, we employed high-throughput sequencing of the “Clonality of Hematopoiesis” targeted gene panel as well as cytogenetic methods. Results. Compensatory somatic events were detected in 31.7% of the patients. The most frequent alterations were genetic variants in the EIF6 gene, as well as the i(7q) and del(20q) clonal cytogenetic abnormalities. Generally, these changes were not accompanied by clinical or morphological signs of myeloid transformation. Conclusion. The obtained data suggest a possible role of somatic genetic compensation in maintaining the viability of hematopoietic cells in SDS. Therefore, the detection of markers of clonal expansion necessitates dynamic molecular monitoring.
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 107-113
Open AccessCompensatory clonal hematopoiesis in patients with Shwachman–Diamond syndrome
Introduction. Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome characterized by a high risk of developing myeloid malignancies. Aim: to determine the spectrum of compensatory genetic events in SDS as well as to analyze their potential role in the clinical course of the disease. Materials and methods. The study included 41 patients with confirmed SDS. For the analysis of somatic alterations, we employed high-throughput sequencing of the “Clonality of Hematopoiesis” targeted gene panel as well as cytogenetic methods. Results. Compensatory somatic events were detected in 31.7% of the patients. The most frequent alterations were genetic variants in the EIF6 gene, as well as the i(7q) and del(20q) clonal cytogenetic abnormalities. Generally, these changes were not accompanied by clinical or morphological signs of myeloid transformation. Conclusion. The obtained data suggest a possible role of somatic genetic compensation in maintaining the viability of hematopoietic cells in SDS. Therefore, the detection of markers of clonal expansion necessitates dynamic molecular monitoring.
- Open Access
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 12-24
The diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol
Introduction. Risk stratification in pediatric acute myeloid leukemia (AML) is traditionally based on the detection of chromosomal rearrangements using conventional molecular cytogenetic methods. However, these approaches are limited in detecting structurally complex and new genomic alterations. Whole-genome sequencing (WGS) overcomes these limitations, ensuring detection of all types of structural variants and providing their comprehensive molecular characterization. Aim: to evaluate the capabilities of WGS in identifying chromosomal rearrangements in children with AML treated under the AML-MRD-2018 protocol. Materials and methods. Out of 723 patients enrolled in the AML-MRD-2018 protocol, 335 (46%) children aged 0–18 years (median age – 9 years) were included in the study. WGS was performed on the DNBSEQ-T7 platform (150 × 2), with a median sequencing depth of 112×. Structural variants were identified using the MANTA algorithm with subsequent verification using a genome visualizer and confirmation by polymerase chain reaction and Sanger sequencing. Results. The results of WGS and standard testing methods were completely concordant in 228 (68%) out of 335 patients. WGS identified key stratifying translocations: KMT2Ar (n = 137; 41%), RUNX1::RUNX1T1 (n = 34; 10%), CBFB::MYH11 (n = 27; 8%), NUP98r (n = 19; 6%). In patients in whom standard methods had failed to detect markers, WGS revealed 26 rearrangements, including cryptic variants of KMT2A (n = 7), NUP98 (n = 5) and ERG rearrangements (n = 2), as well as rare fusion genes. Three novel fusion genes were identified. Overall, WGS provided additional clinically significant information in 40 cases, with an added diagnostic yield of 12%. Conclusion. WGS effectively detects both recurrent and rare, cryptic, and structurally complex chromosomal rearrangements, while providing their thorough molecular characterization. The method allows for improved risk stratification and can serve as a basis for minimal residual disease monitoring, increasing diagnostic accuracy and the potential for treatment personalization.
- 30 June 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 12-24
Open AccessThe diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol
Introduction. Risk stratification in pediatric acute myeloid leukemia (AML) is traditionally based on the detection of chromosomal rearrangements using conventional molecular cytogenetic methods. However, these approaches are limited in detecting structurally complex and new genomic alterations. Whole-genome sequencing (WGS) overcomes these limitations, ensuring detection of all types of structural variants and providing their comprehensive molecular characterization. Aim: to evaluate the capabilities of WGS in identifying chromosomal rearrangements in children with AML treated under the AML-MRD-2018 protocol. Materials and methods. Out of 723 patients enrolled in the AML-MRD-2018 protocol, 335 (46%) children aged 0–18 years (median age – 9 years) were included in the study. WGS was performed on the DNBSEQ-T7 platform (150 × 2), with a median sequencing depth of 112×. Structural variants were identified using the MANTA algorithm with subsequent verification using a genome visualizer and confirmation by polymerase chain reaction and Sanger sequencing. Results. The results of WGS and standard testing methods were completely concordant in 228 (68%) out of 335 patients. WGS identified key stratifying translocations: KMT2Ar (n = 137; 41%), RUNX1::RUNX1T1 (n = 34; 10%), CBFB::MYH11 (n = 27; 8%), NUP98r (n = 19; 6%). In patients in whom standard methods had failed to detect markers, WGS revealed 26 rearrangements, including cryptic variants of KMT2A (n = 7), NUP98 (n = 5) and ERG rearrangements (n = 2), as well as rare fusion genes. Three novel fusion genes were identified. Overall, WGS provided additional clinically significant information in 40 cases, with an added diagnostic yield of 12%. Conclusion. WGS effectively detects both recurrent and rare, cryptic, and structurally complex chromosomal rearrangements, while providing their thorough molecular characterization. The method allows for improved risk stratification and can serve as a basis for minimal residual disease monitoring, increasing diagnostic accuracy and the potential for treatment personalization.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 158-165
Mosaic Li–Fraumeni syndrome in acute lymphoblastic leukemia
Li–Fraumeni syndrome (LFS) is a rare autosomal dominant tumor predisposition syndrome with high penetrance. The pathogenesis of the syndrome involves germline pathogenic variants in the TP53 gene. The spectrum of cancers in LFS predominantly includes solid tumors, with hematologic malignancies occurring in only 4% of cancer diagnoses. Most patients have a family history of the disease, however, in 10–20% of cases, germline variants are de novo. The introduction of next generation sequencing into clinical practice has made it possible to describe rare cases of mosaic LFS syndrome in some patients with solid tumors. This article presents the first described clinical case of mosaic LFS in a patient with hematologic malignancy. This case demonstrates how detailed molecular genetic testing using modern diagnostic techniques can determine the true origin of a pathogenic variant in the TP53 gene. The results of treatment show that, despite existing therapeutic options, patients with hematologic malignancies and LFS, including mosaic LFS, represent a challenging therapeutic group requiring the development of specialized treatment protocols.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 158-165
Open AccessMosaic Li–Fraumeni syndrome in acute lymphoblastic leukemia
Li–Fraumeni syndrome (LFS) is a rare autosomal dominant tumor predisposition syndrome with high penetrance. The pathogenesis of the syndrome involves germline pathogenic variants in the TP53 gene. The spectrum of cancers in LFS predominantly includes solid tumors, with hematologic malignancies occurring in only 4% of cancer diagnoses. Most patients have a family history of the disease, however, in 10–20% of cases, germline variants are de novo. The introduction of next generation sequencing into clinical practice has made it possible to describe rare cases of mosaic LFS syndrome in some patients with solid tumors. This article presents the first described clinical case of mosaic LFS in a patient with hematologic malignancy. This case demonstrates how detailed molecular genetic testing using modern diagnostic techniques can determine the true origin of a pathogenic variant in the TP53 gene. The results of treatment show that, despite existing therapeutic options, patients with hematologic malignancies and LFS, including mosaic LFS, represent a challenging therapeutic group requiring the development of specialized treatment protocols.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 14-36
Interim results of a multicenter study of treatment of patients with acute myeloid leukemia according to the AML-MRD-2018 protocol
Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 14-36
Open AccessInterim results of a multicenter study of treatment of patients with acute myeloid leukemia according to the AML-MRD-2018 protocol
Introduction. Acute myeloid leukemia (AML) is the second most prevalent type of blood malignancy in children that accounts for 15–20% of all pediatric leukemia cases. Before 2018, large-scale prospective studies of AML in children in the Russian Federation were constrained by the absence of both a central pathology review system and centralized monitoring of minimal residual disease (MRD). To address these issues, the national protocol AML-MRD-2018 (NCT03846362) was developed and initiated by the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Materials and methods. This study included 631 patients from 54 clinical facilities across 48 regions of the Russian Federation. Central pathology review was performed at two institutions: the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (Moscow) and Yekaterinburg Regional Children's Clinical Hospital. Risk group stratification was performed in two steps: initially it was based on molecular and genetic characteristics of blast cells, and then (for intermediate risk group) – on response to treatment assessed by MRD testing. Criteria for primary refractoriness and the transfer of patients to a high-risk group were blast cell count (assessed morphologically and immunophenotypically) 5% after induction and MRD ≥ 0.1% after the first course of consolidation. The final stratification was as follows: 67 standard-risk patients, 251 intermediate-risk patients, and 313 high-risk patients. Results. Response to induction therapy was assessable in 580 patients; complete remission was achieved in 84.3% of the cases (n = 489). Treatment effectiveness varied significantly across the risk groups: it was 100% in the standard-risk group (all the patients achieved MRD-negative remission), 91.5% in the intermediate-risk group and 72.9% in the high-risk group (which had the highest proprotion of refractory and MRD positive patients). The first cycle of consolidation therapy according to the protocol was given to 385 patients from the intermediate- and high-risk groups; MRD assessment was performed in 348 cases. MRD-negative remission was achieved in 196 (96%) out of 204 MRD-assessed patients in the intermediate-risk group and in 129 (90%) out of 144 MRD-assessed patients in the high-risk group. The 3-year treatment outcomes in the whole cohort of patients (n = 631) were the following: the overall survival (OS) reached 71% (95% confidence interval (CI) 68–76), the event-free survival (EFS) was 44% (95% CI 40–48), the cumulative risk of relapse (CRR) was 36% (95% CI 31–41). There were significant differences in these parameters between the risk-groups: standard-risk group (n = 67): OS – 84%, EFS – 66%, CRR – 24%; intermediate-risk group (n = 251): OS – 77%, EFS – 50%, CRR – 38%; high-risk group (n = 313): OS – 64%, EFS – 34%, CRR – 37%. Over the period of observation, a total of 255 allogeneic hematopoietic stem cell transplantations (HSCT) were performed. The most common HSCTs were from haploidentical related donors (n = 180; 70%), the graft sources were peripheral blood stem cells (n = 138) and bone marrow (n = 87). The median time from start of therapy to HSCT was 5 months. The 2-year EFS after HSCT was 65% and the 2-year OS post-HSCT was 75%. Conclusion. To date, the potential of universal chemotherapy protocols for AML has been exhausted. Further improvements in treatment outcomes are only possible through the implementation of individualized treatment strategies based on molecular genetic profiling. Promising approaches include the addition of FLT3 inhibitors, gemtuzumab ozogamicin, venetoclax; the inclusion of menin inhibitors in leukemias with KMT2A rearrangements; the integration of hypomethylating agents in the treatment of patients with CBF-AML.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 203-212
Hematologic malignancies in Li–Fraumeni syndrome
Li–Fraumeni Syndrome (LFS) is a rare, autosomal dominant, highly penetrant cancer predisposition syndrome caused by germline mutations in the TP53 (Tumor Protein 53) gene. The classic tumor spectrum of LFS includes adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft tissue sarcomas. Hematologic malignancies (HMs) occur in 4–12% of LFS cases, with a predominance of acute lymphoblastic leukemia characterized by a specific cytogenetic variant – a hypodiploid karyotype. Myelodysplastic syndromes and acute myeloid leukemias are less common and are typically secondary to prior cytotoxic therapy. Given the unfavorable prognosis of HMs in LFS and the necessity of bone marrow transplantation as a curative treatment modality, early identification of this patient group and the selection of an optimal donor who does not carry germline TP53 mutations are of high importance. This review presents the fundamental principles of the pathogenetic basis of LFS and clinical screening criteria, providing a detailed description of the spectrum of HMs in LFS, with specific focus on the clinical and laboratory features of the most common variants.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 203-212
Open AccessHematologic malignancies in Li–Fraumeni syndrome
Li–Fraumeni Syndrome (LFS) is a rare, autosomal dominant, highly penetrant cancer predisposition syndrome caused by germline mutations in the TP53 (Tumor Protein 53) gene. The classic tumor spectrum of LFS includes adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft tissue sarcomas. Hematologic malignancies (HMs) occur in 4–12% of LFS cases, with a predominance of acute lymphoblastic leukemia characterized by a specific cytogenetic variant – a hypodiploid karyotype. Myelodysplastic syndromes and acute myeloid leukemias are less common and are typically secondary to prior cytotoxic therapy. Given the unfavorable prognosis of HMs in LFS and the necessity of bone marrow transplantation as a curative treatment modality, early identification of this patient group and the selection of an optimal donor who does not carry germline TP53 mutations are of high importance. This review presents the fundamental principles of the pathogenetic basis of LFS and clinical screening criteria, providing a detailed description of the spectrum of HMs in LFS, with specific focus on the clinical and laboratory features of the most common variants.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 68-73
Somatic oncogenic events in Shwachman–Diamond syndrome: molecular genetic characterization and clinical significance
Introduction. Shwachman–Diamond syndrome (SDS) is a hereditary bone marrow failure syndrome associated with an increased risk of myeloid neoplasms. Somatic genetic events play a significant role in the pathogenesis of malignant transformation in SDS; however, their clinical significance remains understudied. Aim. To study the spectrum of somatic genetic and cytogenetic changes in patients with SDS and their potential association with myeloid transformation. Materials and methods. The study included 41 patients with SDS. High-throughput sequencing using the “Clonality of Hematopoiesis” targeted gene panel and cytogenetic testing by fluorescence in situ hybridization were performed. The frequency, type, and variant allele frequency (VAF) of the somatic variants were analyzed. Results. Somatic transforming events were detected in 21.9% of the patients. Most commonly found were variants in the TP53 gene, mainly with low VAF and no signs of malignant transformation. Myeloid neoplasms developed in the presence of high-VAF mutations or alternative oncogenic events. Conclusion. The obtained data demonstrate the heterogeneity of myeloid transformation pathways in SDS and highlight the need for comprehensive molecular genetic testing in the clinical monitoring of affected patients.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 68-73
Open AccessSomatic oncogenic events in Shwachman–Diamond syndrome: molecular genetic characterization and clinical significance
Introduction. Shwachman–Diamond syndrome (SDS) is a hereditary bone marrow failure syndrome associated with an increased risk of myeloid neoplasms. Somatic genetic events play a significant role in the pathogenesis of malignant transformation in SDS; however, their clinical significance remains understudied. Aim. To study the spectrum of somatic genetic and cytogenetic changes in patients with SDS and their potential association with myeloid transformation. Materials and methods. The study included 41 patients with SDS. High-throughput sequencing using the “Clonality of Hematopoiesis” targeted gene panel and cytogenetic testing by fluorescence in situ hybridization were performed. The frequency, type, and variant allele frequency (VAF) of the somatic variants were analyzed. Results. Somatic transforming events were detected in 21.9% of the patients. Most commonly found were variants in the TP53 gene, mainly with low VAF and no signs of malignant transformation. Myeloid neoplasms developed in the presence of high-VAF mutations or alternative oncogenic events. Conclusion. The obtained data demonstrate the heterogeneity of myeloid transformation pathways in SDS and highlight the need for comprehensive molecular genetic testing in the clinical monitoring of affected patients.
- Open Access
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 167-174
Acute myeloid leukemia with translocations involving the KMT2A gene in twins as a model for the study of leukemogenesis: clinical case reports and genetic characteristics
Familial cases of acute leukemia in children are very rare and are mainly reported in cases of genetically determined predisposition syndromes (mutations in the RUNX1, ETV6, ANKRD26, GATA2, SAMD9/SAMD9L, CEBPA genes) which have been well characterized in the last 15 years. In twins, leukemia is even more rare and is of particular interest for the study of leukemogenesis patterns and evolution of leukemic subclones. Here, we report about three pairs of twins: in one pair, KMT2A-r-leukemia was diagnosed simultaneously, while in the other two cases the second child remained healthy despite the development of KMT2A-r-leukemia in their twin. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 167-174
Open AccessAcute myeloid leukemia with translocations involving the KMT2A gene in twins as a model for the study of leukemogenesis: clinical case reports and genetic characteristics
Familial cases of acute leukemia in children are very rare and are mainly reported in cases of genetically determined predisposition syndromes (mutations in the RUNX1, ETV6, ANKRD26, GATA2, SAMD9/SAMD9L, CEBPA genes) which have been well characterized in the last 15 years. In twins, leukemia is even more rare and is of particular interest for the study of leukemogenesis patterns and evolution of leukemic subclones. Here, we report about three pairs of twins: in one pair, KMT2A-r-leukemia was diagnosed simultaneously, while in the other two cases the second child remained healthy despite the development of KMT2A-r-leukemia in their twin. The patients’ parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- Open Access
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1)
ОМЛ с транслокациями, вовлекающими ген КМТ2А, у близнецов как модель для исследования лейкемогенеза: описание клинических случаев и генетические характеристики.
Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал
- 28 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1)
Open AccessОМЛ с транслокациями, вовлекающими ген КМТ2А, у близнецов как модель для исследования лейкемогенеза: описание клинических случаев и генетические характеристики.
Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал
- Open Access
- 27 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 106-115
Leukemia with L3 morphology: cytogenetic characterization and diagnostic challenges
Burkitt lymphoma/leukemia (BL) is a highly aggressive B-cell non-Hodgkin lymphoma with a strong predilection for extranodal involvement and frequent multi-organ dissemination. When the bone marrow is affected, BL is typically characterized by three key signs: L3 morphology as defined by the French-American-British classification, a MYC gene rearrangement, and a mature immunophenotype with surface immunoglobulin expression as confirmed by flow cytometry. However, in some BL cases, some of these features may be absent. Here, we studied a correlation between L3 morphology and the presence of MYC gene rearrangements in the bone marrow. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Out of the 127 patients with L3 morphology, 89.8% (n = 114) harbored MYC rearrangements, while in the patients with L1/L2 morphology such rearrangements were extremely rare (0.1%; 2 out of 2049). We identified the following MYC rearrangements: t(8;14)(q24;q32)/IGH::MYC (91.2%; n = 104), t(8;22)(q24;q11)/IGK::MYC (7.0%; n = 8), t(2;8)(p12;q24)/IGL::MYC (1%; n = 1), and t(8;14)(q24;q32)/IGH::MYC combined with t(14;18)(q32;q21)/IGH::BCL2 (n = 1). At the same time, 13 patients with L3 morphology did not have MYC rearrangements. Among these cases, 69.2% (n = 9) of patients harbored other chromosomal aberrations commonly associated with B-lineage acute lymphoblastic leukemia, including rearrangements involving the KMT2A and ETV6 genes and IGH locus, as well as hyperdiploidy and hypodiploidy. According to the findings of the initial analysis of cytogenetic samples using the fluorescence in situ hybridization (FISH) method, 23.6% (n = 25) of the MYC-positive cases either did not have abnormal cells or had a minimal amount. In such cases, MYC positivity was reliably confirmed by FISH performed on morphological samples with established blastosis. Notably, the percentage of blast cells varied significantly among the MYC-positive samples depending on the puncture site, which can potentially lead to false negative cytogenetic results. However, this variation was much lower in other genetic alterations such as hyperdiploidy, KMT2A rearrangements, and t(12;21)(p13;q22)/ETV6::RUNX1. Therefore, if there are any discrepancies between the results of morphological and cytogenetic analyses, it is recommended to perform additional testing using morphological smears with previously confirmed blastosis with L3 morphology.
- 27 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 106-115
Open AccessLeukemia with L3 morphology: cytogenetic characterization and diagnostic challenges
Burkitt lymphoma/leukemia (BL) is a highly aggressive B-cell non-Hodgkin lymphoma with a strong predilection for extranodal involvement and frequent multi-organ dissemination. When the bone marrow is affected, BL is typically characterized by three key signs: L3 morphology as defined by the French-American-British classification, a MYC gene rearrangement, and a mature immunophenotype with surface immunoglobulin expression as confirmed by flow cytometry. However, in some BL cases, some of these features may be absent. Here, we studied a correlation between L3 morphology and the presence of MYC gene rearrangements in the bone marrow. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Out of the 127 patients with L3 morphology, 89.8% (n = 114) harbored MYC rearrangements, while in the patients with L1/L2 morphology such rearrangements were extremely rare (0.1%; 2 out of 2049). We identified the following MYC rearrangements: t(8;14)(q24;q32)/IGH::MYC (91.2%; n = 104), t(8;22)(q24;q11)/IGK::MYC (7.0%; n = 8), t(2;8)(p12;q24)/IGL::MYC (1%; n = 1), and t(8;14)(q24;q32)/IGH::MYC combined with t(14;18)(q32;q21)/IGH::BCL2 (n = 1). At the same time, 13 patients with L3 morphology did not have MYC rearrangements. Among these cases, 69.2% (n = 9) of patients harbored other chromosomal aberrations commonly associated with B-lineage acute lymphoblastic leukemia, including rearrangements involving the KMT2A and ETV6 genes and IGH locus, as well as hyperdiploidy and hypodiploidy. According to the findings of the initial analysis of cytogenetic samples using the fluorescence in situ hybridization (FISH) method, 23.6% (n = 25) of the MYC-positive cases either did not have abnormal cells or had a minimal amount. In such cases, MYC positivity was reliably confirmed by FISH performed on morphological samples with established blastosis. Notably, the percentage of blast cells varied significantly among the MYC-positive samples depending on the puncture site, which can potentially lead to false negative cytogenetic results. However, this variation was much lower in other genetic alterations such as hyperdiploidy, KMT2A rearrangements, and t(12;21)(p13;q22)/ETV6::RUNX1. Therefore, if there are any discrepancies between the results of morphological and cytogenetic analyses, it is recommended to perform additional testing using morphological smears with previously confirmed blastosis with L3 morphology.